Why AI Isn't Ready to Make Medicines

Podcast: TechSurge: Deep Tech Podcast · Celesta Capital | Deep Tech Venture Capital Firm

Opublikowano: 2025-03-13

Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do? In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis’ unique system which combines laser printed human organoids and an externalized human immune system with AI...